Core Viewpoint - 博瑞医药 has abruptly withdrawn its plan for a private placement of A-shares for 2024, citing current market conditions and company circumstances as reasons for the decision [2] Group 1: Company Actions - The company initially planned to raise 500 million yuan through a private placement led by its actual controller, Yuan Jiandong, which was approved by the board and shareholders in May 2024 [2] - After a year of no progress on the private placement, the company revised its issuance plan multiple times before ultimately retracting the application [2][3] Group 2: Stock Price Fluctuations - 博瑞医药's stock price experienced significant volatility, rising from around 30 yuan to approximately 120 yuan within a month starting July 11, before plummeting back to 55.31 yuan [3] - The stock's dramatic rise and fall over three months has been likened to a "roller coaster" [3] Group 3: Financial Performance - The company's financial performance has deteriorated sharply, with net profit dropping by 84% to just over 17 million yuan in the first half of 2025 [4] - Revenue figures show a consistent decline, with total revenue for 2024 projected at 1.283 billion yuan, down from 1.180 billion yuan in 2023 [5] - The company reported a decline in net profit from 2022 onwards, with a significant drop in growth rates, indicating a troubling trend in profitability [5] Group 4: Company Background - 博瑞医药 is described as an innovative pharmaceutical company focused on research and development, aiming to establish a robust business model that integrates both generic and innovative drugs [5] - The company has undergone multiple rounds of financing since its IPO in 2019, including convertible bonds and a private placement, but faced regulatory scrutiny due to issues with fund management [6]

【 导读 】 博瑞医药定增筹划近一年半突然撤回，净利润暴跌八成，股价暴涨暴跌 记者注意到，近一年尤其是最近的三个月，博瑞医药股价出现了急剧变化。最初发行预案公布时，公司股价尚在30元附近，实控人独揽定 增无疑是合算的"买卖"，但随着"9·24"行情启动，加上今年以来创新药概念热炒，博瑞医药股价出现了大幅上涨的情况。 尤其是从7月11日开始之后的一个月，其股价更是快速上涨，短短一个月从55元最高涨到120元附近，8月中旬开始又持续暴跌，目前最新 股价跌到了55.31元。短短三个月，博瑞医药股价就坐了一轮大大的"过山车"。 除了股价，博瑞医药的业绩也出现了急剧变化，公司2019年在科创板上市，起初几年还能保持业绩正增长，但2022年开始出现小幅下滑， 2023年、2024年保持下滑趋势。到了2025年，公司业绩从小幅下滑转为断崖式下滑，今年上半年净利润仅有1700余万元，暴跌了 84%。 | 成长能力指标 | 24-12-31 | 23-12-31 | 22-12-31 | 21-12-31 | 20-12-31 | 19-12-31 | | --- | --- | --- | --- | --- | --- | ...

Core Viewpoint - The company plans to invest up to RMB 10 million in the Suzhou Rongxin Health Industry Venture Capital Center (Limited Partnership), focusing on innovative pharmaceutical products and technologies, which aligns with its main business [1][2]. Investment Overview - The investment aims to leverage the expertise of professional investment institutions to identify early-stage investment opportunities in high-potential areas such as innovative pharmaceuticals and complex formulations [2]. - The company will not guarantee minimum returns or exit guarantees for other investors in the fund [2]. Fund Management - The fund will be managed by Suzhou Rongshi Private Equity Fund Management Co., Ltd., which has a registered capital of RMB 10 million and manages funds ranging from RMB 1 billion to 2 billion [3]. - The fund is currently in the preparation and fundraising stage, with other partners yet to be fully determined [4]. Agreement and Compliance - As of the announcement date, the partnership agreement has not been signed, and the specifics will be determined by the final agreement [4]. - The investment does not constitute a related party transaction or a major asset restructuring as per regulatory definitions [2]. Financial Impact - The investment will not be consolidated into the company's financial statements and will not impose financial pressure on the company's existing operations [4]. - The funding source for the investment is the company's own funds, ensuring that normal business operations remain unaffected [4]. Risk Analysis - The investment process carries uncertainties, including the potential failure to raise sufficient funds due to partners not fulfilling their capital commitments [5]. - The company, as a limited partner, will have limited control over the fund's investment risks and will enhance communication with partners to monitor fund operations [5].